Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology - Medical City
mi
from
Dallas, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology - Dallas
mi
from
Dallas, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology -El Paso
mi
from
El Paso, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology -El Paso
mi
from
El Paso, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology - Garland
mi
from
Garland, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology - Garland
mi
from
Garland, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology - Memorial City
mi
from
Houston, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology- Lewisville
mi
from
Lewisville, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology- Lewisville
mi
from
Lewisville, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology - McAllen
mi
from
McAllen, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology - McAllen
mi
from
McAllen, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology-Plano East
mi
from
Plano, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology-Plano East
mi
from
Plano, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Texas Oncology-Tyler
mi
from
Tyler, TX
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Yakima Valley Memorial Hospital
mi
from
Yakima, WA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Yakima Valley Memorial Hospital
mi
from
Yakima, WA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Arizona Oncology Associates
mi
from
Tuscon, AZ
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Arizona Oncology Associates
mi
from
Tuscon, AZ
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Wilshire Oncology Medical Group
mi
from
Rancho Cucamonga, CA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Wilshire Oncology Medical Group
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Georgia Cancer Specialists
mi
from
Marietta, GA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Georgia Cancer Specialists
mi
from
Marietta, GA
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Illinois Cancer Specialists
mi
from
Niles, IL
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Illinois Cancer Specialists
mi
from
Niles, IL
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Cooper Cancer Institute
mi
from
Voorhees, NJ
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Cooper Cancer Institute
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated:  2/14/2016
Puget Sound Cancer Center
mi
from
Seattle, WA
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: Enrolling
Updated: 2/14/2016
Puget Sound Cancer Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II)
Status: Enrolling
Updated:  2/15/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II)
Status: Enrolling
Updated: 2/15/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Biological Therapy in Treating Women With Stage IV Breast Cancer
Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date)
Status: Enrolling
Updated:  2/15/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Biological Therapy in Treating Women With Stage IV Breast Cancer
Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date)
Status: Enrolling
Updated: 2/15/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With The Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/15/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With The Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/15/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Status: Enrolling
Updated:  2/17/2016
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Status: Enrolling
Updated: 2/17/2016
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Status: Enrolling
Updated:  2/17/2016
PrECOG
mi
from
Philadelphia, PA
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Status: Enrolling
Updated: 2/17/2016
PrECOG
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer
Women In Steady Exercise Research (WISER) Sister
Status: Enrolling
Updated:  2/17/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer
Women In Steady Exercise Research (WISER) Sister
Status: Enrolling
Updated: 2/17/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
University of California at San Francisco
mi
from
San Francisco, CA
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
Georgetown University
mi
from
Washington,
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
University of Chicago
mi
from
Chicago, IL
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
Johns Hopkins University
mi
from
Baltimore, MD
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
University of Michigan
mi
from
Ann Arbor, MI
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
University of North Carolina-CH Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
University of North Carolina-CH Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
Duke University
mi
from
Durham, NC
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
Vanderbilt University
mi
from
Nashville, TN
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated:  2/17/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: Enrolling
Updated: 2/17/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bone Response in Metastatic Breast Cancer Involving Bones
Prospective Study of Tumor Response Assessment in Metastatic Breast Cancer Involving Bones
Status: Enrolling
Updated:  2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Bone Response in Metastatic Breast Cancer Involving Bones
Prospective Study of Tumor Response Assessment in Metastatic Breast Cancer Involving Bones
Status: Enrolling
Updated: 2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
The Impact of Obesity and Obesity Treatments on Breast Cancer
The Impact of Obesity and Obesity Treatments on Breast Cancer: A Phase I Trial of Exemestane With Metformin and Rosiglitazone for Postmenopausal Obese Women With ER+ Metastatic Breast Cancer
Status: Enrolling
Updated:  2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
The Impact of Obesity and Obesity Treatments on Breast Cancer
The Impact of Obesity and Obesity Treatments on Breast Cancer: A Phase I Trial of Exemestane With Metformin and Rosiglitazone for Postmenopausal Obese Women With ER+ Metastatic Breast Cancer
Status: Enrolling
Updated: 2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated:  2/17/2016
Scottsdale Medical Imaging, Limited (SMIL)
mi
from
Scottsdale, AZ
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated: 2/17/2016
Scottsdale Medical Imaging, Limited (SMIL)
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated:  2/17/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated: 2/17/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated:  2/17/2016
Elizabeth Wende Breast Care, LLC (EWBC)
mi
from
Rochester, NY
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated: 2/17/2016
Elizabeth Wende Breast Care, LLC (EWBC)
mi
from
Rochester, NY
Click here to add this to my saved trials
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated:  2/17/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated: 2/17/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated:  2/17/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study
Status: Enrolling
Updated: 2/17/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers
Status: Enrolling
Updated:  2/18/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers
Status: Enrolling
Updated: 2/18/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Status: Enrolling
Updated:  2/18/2016
GSK Investigational Site
mi
from
Little Rock, AR
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Status: Enrolling
Updated: 2/18/2016
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials